Clinical Studies

Sarah Averbach, MD, MAS

(Inclusion): Postpartum people aged 18 and older, reside in rural Maharashtra, speak Marathi, delivered a baby within the past 8 weeks but did not undergo sterilization, hysterectomy or immediate postpartum IUD placement and do not have a new pregnancy.

(Exclusion): Under 18 years old, delivered a baby more than 8 weeks prior or planning to move out of the study area within the next 6 months. 

(Inclusion): 18 years and older, speak English or Spanish, had a vaginal or cesarean delivery of a singleton full-term (>37weeks) infant less than 168 hours prior.

(Exclusion:) Patients who desire another pregnancy in less than 6 months, do not intend to exclusively breastfeed, do not have access to a smartphone, email or telephone, or have any medical contraindication to progestin-only pills (POPs) per the U.S. CDC MEC or any contraindication to breastfeeding. In addition, people with known current illegal maternal drug use, a history of breast reduction or augmentation, or an infant with a major congenital anomaly due to unique challenges with breastfeeding.

(Inclusion): Patients who gave birth less than or equal to 10 days ago, desires an IUD for contraception (either copper or levonorgestrel contraining), willinf and able to sign an informed consent, willing to comply with the study protocol, age great than or equal to 18 years, English or Spanish speaking.

(Exclusion): Uterine anomaly or leiomyomata which would not allow placement of an IUD, desire for repeat pregnancy in less than 6 months, evidence of intra-uterine infection (chorioamnionitis or postpartum endometritis) treated with antibiotics, ruptured uterus at the time of delivery, received a postpartum tubal ligation or immediate postpartum IUD or implant at delivery, incarcerated women or women with significant cognitive impairment, 4th degree perineal laceration sustained at delivery, any medical contraindication to IUD per the US CDC Medical Eligibility Criteria, any suspicion for new pregnancy.  

(Inclusion): 18 years or older; Less than 23 weeks and 6 days; Having had one of the following ICD-10 procedures (59840, 59841, 59820, 59821)

(Exclusion): If they underwent an induction termination or a medication abortion; If they underwent admission or procedure as a result of an outside facility transfer

(Inclusion): Over 18. Nexplanon user. Has appointment to replace nexplanon.

(Exclusion): Has had nexplanon for less that 32 months or more than 40 months.

(Inclusion): persons with a prior cesarean section undergoing an induction of labor either electively or for medical indication after 34 weeks with a live, singleton gestation in cephalic presentation.

(Exclusion): persons with multiple gestation, fetal demise, malpresentation, contraindication to vaginal delivery, those who present with spontaneous labor, cases of labor augmentation, those who undergo planned elective repeat cesarean section, or for whom available data is insufficient.

(Inclusion): Patients must be 28-32 weeks gestational age, English or Spanish speaking, over 18 years old, not planning on a cesarean delivery, and see high risk OB (MFM) for prenatal care.

(Exclusion): Planning a cesarean section, under 18, primary language other than English or Spanish, see a prenatal provider who is not a high risk OB

(Inclusion):

• 18 years of age or older
• At risk for delivery between GA 22.0-23.6
• Counseled by NICU and MFM regarding resuscitation options

(Inclusion):

• 18 years of age or older
• Gestational age18 0/7 to 20 6/7 weeks
• Singleton intrauterine pregnancy
• No signs and/or symptoms of preterm labor and has intact membranes

(Inclusion):

• Pregnant women 18 years of age to 50 years of age
• 10-24 weeks gestation at time of enrollment
• Singleton pregnancy
• Planning to deliver at a study site

(Exclusion):

• Inability to give informed consent
• Intrauterine fetal demise
• Fetal genetic or structural anomaly
• Institutionalization for psychiatric disorder, mental deficiency or incarcerated
• Active or history of malignancy requiring major surgery or systemic chemotherapy
• Multi-fetal gestation or a twin demise at any gestational age
• Known maternal or fetal chromosomal anomalies
• Patients who plan to keep their placenta after delivery

(Inclusion):

• Age 18 years or older
• Speak Spanish or English
• Cohort 2 Testing Group:
• Speak Spanish and/or English.
• Affiliated with San Ysidro Health as a patient at select clinics (San Ysidro, Chula Vista, Lincoln Park, and Logan Heights) OR
• A member of a community near a SYH clinic (San Ysidro, Chula Vista, Lincoln Park, and Logan Heights).
• Ages 2 and older (for use of FDA-authorized antigen test kits)
• Cohort 3 Healthcare Providers/Staff/Administrators:
• Speaks Spanish and/or English.
• Employed as a SYH clinical provider, administrator, or clinical staff member at a participating clinic

(Inclusion): Non-diagnostic results of chromosomal microarray and/or karyotype and No evidence of:

• Clinically significant abruption that is suspected to underlie NIHF
• Twin-twin transfusion syndrome in monochorionic twins;
• Clear fetal viral infection;
• Alloimmunization.

AND ONE OF THE FOLLOWING

• i) Increased nuchal translucency or cystic hygroma ≥5 mm WITHOUT any additional fetal effusions or anomalies;

AND/OR

• ii) Increased nuchal translucency or cystic hygroma ≥3.5 mm AS WELL AS either any additional fetal effusions or congenital anomalies;

AND/OR

• iii) Fetal ascites, pleural effusion, pericardial effusion, AND/OR skin edema identified at any point during gestation, prior to the conclusion of the pregnancy.

(Inclusion):GA≥10Wks, available results form NIPT standard

(Exclusion):Failure to meet inclusion criteria

(Inclusion):

• Female age ≥18 years of age
• Able to provide informed consent
• Fetal gestational age 24-42 weeks at time of consent
• Surrogates and/or use of donor eggs/donor sperm for conception is allowed

(Inclusion):

• Female age >18 years of age
• Able to provide informed consent
• Able to provide acceptable answers to Donor/Subject Questionnaire
• Giving birth at a licensed hospital-based Labor and Delivery (L&D) Unit
• Neonatal gestational age 24-42 weeks at time of consent
• History of prolonged rupture of membranes with no maternal fever before birth is allowed
• History of maternal diabetes or hypertension is allowed
• Surrogates and/or use of donor eggs/donor sperm for conception is allowed
• Multiple gestation pregnancy is allowed

(Inclusion):

• Pregnant patients ≥ 18 years of age.
• Agrees to allow for the placenta to be sent to Pathology for evaluation.

Inclusion criteria for the Non-pregnant group:

• Non-pregnant women ≥ 18 years of age.
• Healthy women with no previous history of chronic hypertension or renal disease.

Inclusion criteria for cases:

• Pregnant women ≥18 years of age
• Presenting for care in one of the listed health care systems
• Diagnosis of suspected placenta accreta, diagnosed by ultrasound or magnetic resonance imaging
• Planning to deliver within the listed health care system
• Agrees to allow for the placenta to be sent to Pathology for evaluation

(Inclusion): Diagnosis of GDM in pregnancy

(Exclusion): Pre-existing diabetes, use of APP independently

Beta-Agonist versus Botox A® Trial for Urgency Urinary Incontinence (BEST)

Discover "Best" Research Study

1. 18 years or older
2. report at least "quite a bit bothered" or worse by their UUI defined by response to OAB-q-SS item #8 "How bothered are you by urine loss associated with a strong desire to urinate?"
3. are not and do not plan to become pregnant
4. have persistent UUI defined as previous unsuccessful results after conservative and anticholinergic treatment, or are unable to tolerate or have contraindications to anticholinergics
5. are currently not taking anticholinergics or are willing to stop medication for 3 weeks prior to enrollment.

Emily Lukacz, MD, MAS